SAN DIEGO—(BUSINESS WIRE)—Aug. 3, 2006—ACADIA PharmaceuticalsInc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will present at the following investor conferences:
—The Canaccord Adams 26th Annual Summer Seminar on Thursday,August 10, 2006, at 1:00 p.m. Eastern Time at the BostonMarriott Long Wharf Hotel in Boston, Massachusetts.
—The Bank of America 2006 Specialty Pharmaceuticals Conferenceon Friday, August 11, 2006, at 9:45 a.m. Eastern Time at theSouthampton Inn in Southampton, New York.
Live webcasts of these presentations will be accessible on thecompany's website, www.acadia-pharm.com, under the investors sectionand an archived recording will be available on the website throughAugust 25, 2006.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive Phase II-stage clinical programs as well as a portfolio ofpreclinical and discovery assets directed at large unmet medicalneeds, including schizophrenia, Parkinson's disease, sleep maintenanceinsomnia, and neuropathic pain. All of the drug candidates in ACADIA'sproduct pipeline emanate from discoveries made using its proprietarydrug discovery platform. ACADIA's corporate headquarters is located inSan Diego, California and it maintains research and developmentoperations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief FinancialOfficer
(858) 558-2871